BeiGene’s (BGNE) BTK-targeting chimeric degradation activation compound designed to degrade wildtype BTK and multiple mutant forms received FDA orphan designation in treatment of Waldenstrom macroglobulinemia, according to a post on the agency’s site.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BGNE: